Are Peptides Legal in 2026? The FDA Reclassification Explained

What Happened: The RFK Peptide Announcement

On the Joe Rogan Experience podcast (aired February 28, 2026), HHS Secretary RFK Jr. announced his intention to reverse the Biden-era FDA ban on compounding certain peptides. Key points from the announcement:

• Approximately 14 of 19 restricted peptides will move from Category 2 to Category 1
• He called the original ban "illegal," arguing the FDA lacked the required safety signal to justify restrictions
• He argued the ban pushed consumers to the unregulated gray market: "We created the gray market"
• The reclassification would go through the FDA's normal advisory-committee process rather than take effect overnight
• 5 peptides with weaker safety profiles will remain restricted

What Category 1 and Category 2 Mean

The FDA uses a category system to classify bulk drug substances for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act:

Which Peptides Are Affected

The 14 Peptides Expected to Return to Legal Compounding

Based on the announcement and available analysis, these peptides are expected to move from Category 2 to Category 1:

Five of these (AOD-9604, CJC-1295, Ipamorelin, Thymosin Alpha-1, and Selank) were already removed from Category 2 in September 2024 and referred to the Pharmacy Compounding Advisory Committee (PCAC) for review.

The 5 Peptides Expected to Remain Restricted

The exact final list has not been officially published. Some uncertainty remains about which 5 will stay restricted.

The July 2026 PCAC Vote: What's Actually on the Agenda

How the committee actually voted

Three things about that table matter more than the headline:

• The committee overruled the FDA's own scientists. FDA staff recommended against inclusion for all seven, saying the evaluation criteria "weigh against" placing these substances on the list, citing limited evidence of effectiveness and the availability of alternative treatments. Six went through anyway.
• The margins were thin. BPC-157 and KPV cleared by two votes; epitalon by two; emideltide failed by one. This was not a consensus.
• The votes are advisory. Per the FDA's own process, "the committee's recommendation is not a binding decision, and the addition of the peptides to the list will still have to go through a lengthy public rulemaking process." The agency can decline the recommendation entirely.

Popular peptides that are NOT on the July vote

This is where most online coverage gets it wrong — including a widely shared thread from a cardiologist that listed several of these as being reviewed in July. They are not on the July 23–24 agenda:

Reclassification is not FDA approval

The Five Legal Tiers of Peptide Status

Not all peptides have the same legal standing. Here is how the different categories work in practice:

Tier 1: FDA-Approved Drugs

These peptides completed full clinical trials and received FDA marketing authorization. Legal to prescribe, covered by some insurance plans.

Tier 2: Legal Compounded Peptides (Category 1)

This is the category that the reclassified peptides would enter.

Tier 3: Banned Compounds (Category 2)

These are prohibited from compounding. Any pharmacy offering them is operating illegally. This is the category that the 14 peptides are expected to leave.

Tier 4: Investigational Drugs

Tier 5: Gray Market "Research Chemicals"

Peptides sold online labeled "for research purposes only." Purchasing them is not illegal for consumers, but they are not regulated by the FDA, quality varies widely, and marketing them for human use is illegal. The RFK reclassification aims to move consumers away from this tier and into supervised medical care.

How This Relates to GLP-1 Drugs

• Semaglutide and tirzepatide are NOT among the 19 peptides being reclassified. They are FDA-approved drugs with a completely different regulatory pathway.
• The FDA declared the semaglutide shortage resolved in February 2025, ending the legal basis for compounding pharmacies to produce copies. Compounding of semaglutide has been wound down.
• Retatrutide is NOT affected by the reclassification. It is an investigational drug that cannot be compounded under any circumstance.

However, some reclassified peptides are marketed as weight loss alternatives:

• AOD-9604 — a growth hormone fragment studied for fat metabolism (failed its Phase 2b trial)
• MOTS-C — a mitochondrial peptide with no human weight loss clinical evidence
• CJC-1295 + Ipamorelin — growth hormone secretagogues with zero human weight loss trials

Timeline of the Peptide Ban

What This Means for Consumers

What You Can Do

• Get FDA-approved GLP-1 drugs (semaglutide, tirzepatide) with a valid prescription from any licensed pharmacy
• Enroll in clinical trials for investigational drugs like retatrutide through ClinicalTrials.gov
• Read the July 23–24, 2026 PCAC result correctly — six of seven peptides were recommended, not legalized. Eligible for review is not the same as legal to compound
• Watch for the FDA rulemaking that follows the vote — that, not the committee, is what actually changes the law, and the agency can still decline
• Once reclassification is formalized: obtain Category 1 peptides from licensed compounding pharmacies with a valid prescription from a healthcare provider

What You Cannot Do

• Obtain compounded Category 2 peptides — until the reclassification is formally published, they remain banned
• Get compounded semaglutide — the shortage has been resolved and compounding is no longer permitted
• Purchase retatrutide for human use — it is an investigational drug available only through clinical trials
• Rely on "research use only" peptides for medical treatment — these are unregulated products

Frequently Asked Questions

Sources

• Regulatory Affairs Professionals Society (RAPS). (2026). FDA advisory committee backs two more peptides, rejects one for compounding list. raps.org.
• TIME. (2026, July 23). An FDA Committee Just Voted in Favor of Peptides — Despite the Agency's Opposition. time.com.
• STAT News. (2026, July 23). FDA advisory panel narrowly votes to allow compounding of unapproved peptides. statnews.com.
• FDA. (2026). Meeting of the Pharmacy Compounding Advisory Committee, July 23–24, 2026. fda.gov.
• BioPharma Dive. (2026). FDA moves toward easing restrictions on certain peptides. biopharmadive.com.
• Gizmodo. (2026). RFK Jr. Tells Joe Rogan He's About to Unleash 14 Banned Peptides. gizmodo.com.
• FDA. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. fda.gov.
• Reed Smith LLP. (2024). FDA removes certain peptide bulk drug substances from Category 2. Lexology.
• DJ Holt Law. (2026). Regulatory Alert: The Legal Status of BPC-157. djholtlaw.com.
• FierceHealthcare. (2025). FDA declares semaglutide shortage over. fiercehealthcare.com.
• Health Law Alliance. (2026). FDA Targets GLP-1 and Peptide Compounding. healthlawalliance.com.